Compare Tilray Brands Inc (TLRY) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tilray Brands Inc vs DENTSPLY SIRONA Inc — how do they compare? Tilray Brands Inc trades at $3.63 (market cap $530.54M), while DENTSPLY SIRONA Inc trades at $8.67 (market cap $1.73B). The key difference: DENTSPLY SIRONA Inc is far larger — about 3.3× Tilray Brands Inc's market cap, and DENTSPLY SIRONA Inc pays a 5.04% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Tilray Brands Inc for 31 Days and DENTSPLY SIRONA Inc for 72 Days on average.
| TLRY | XRAY | |
|---|---|---|
Market Cap | $530.54M | $1.73B |
Volume | 9,099,075 | 6,198,582 |
Sector | Health | Health |
52-Week High | $21.00 | $14.68 |
52-Week Low | $3.57 | $8.52 |
Typical Hold Time | 31 Days | 72 Days |
Enterprise Value | $684.46M | $3.80B |
Dividend Yield | — | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TLRY trades at $3.715, down 1.72% on the day and near its 52-week low, reflecting persistent bearish technical momentum. The company reported revenue of $821.31M in 2025 but a substantial net loss of -$2.19B, with negative cash flow from operations. Recent quarters show consistent earnings misses versus expectations, though analyst consensus suggests a high price target of $65.01 amid mixed sentiment.
The outlook remains challenged by profitability issues and high debt, but potential catalysts include U.S. cannabis regulatory changes. Investment opportunities hinge on speculative regulatory shifts, while risks include ongoing losses, competitive pressures, and reliance on financing activities to sustain operations.
DENTSPLY SIRONA (XRAY) trades at $8.54, near a 52-week low, with a bearish technical signal from moving averages. The company reported a Q2 2026 earnings beat but faces declining revenues and negative net income margins. Recent news highlights institutional stake increases and ongoing turnaround efforts amid sales weakness in dental segments.
The outlook remains challenging due to persistent profitability issues and high debt, though analyst consensus suggests upside to a $13.40 price target. Key risks include margin pressure and competitive threats, while potential catalysts include successful restructuring and digital dentistry growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
